Search - tctmd.com

Displaying 1 - 20 of 337

Sort: Relevancy | Date

News Conference News TCT 2025

Sirolimus-Coated Balloon Meets Mark in De Novo Lesions and ISR: SELUTION

Michael O'Riordan

October 26, 2025

News Daily News

Coronary DCB Works Well in Multilayer In-Stent Restenosis: AGENT IDE Subanalysis

L.A. McKeown

August 12, 2025

News Conference News CRT 2025

AGENT IDE: DCB Performance for In-Stent Restenosis Lasts Out to 2 Years

L.A. McKeown

March 10, 2025

News Daily News

DES Best for In-Stent Restenosis, but DCBs Also Viable

Michael O'Riordan

August 13, 2024

News Daily News

DCB in STEMI Match DES Through 5 Years: REVELATION

Caitlin E. Cox

March 27, 2024

News Conference News CRT 2024

Mixed Bag With DCBs for In-Stent Restenosis, Small Coronary Arteries

L.A. McKeown

March 14, 2024

News Conference News CRT 2024

Full AGENT IDE Results Affirm Benefits of DCB for In-Stent Restenosis

L.A. McKeown

March 09, 2024

News Daily News

UK Cardiac Audit Reveals Some Good, Some ‘Appalling’ Trends in PCI

L.A. McKeown

February 06, 2024

News Conference News TCT 2023

BIOSTEMI: Degradable-Polymer, Ultrathin-Strut DES Shows No Late Catch-up at 5 Years

Caitlin E. Cox

October 27, 2023

News Conference News TCT 2023

‘Light at the End of the Tunnel’ for In-Stent Restenosis: AGENT IDE Wins Big

Todd Neale

October 25, 2023

News Daily News

Long-term Data Support Paclitaxel-Coated Balloons for In-Stent Restenosis

Michael O'Riordan

February 24, 2023

News Conference News EuroPCR 2022

Long-term Outcomes With PCI and CABG: More Analyses to Stir the Pot

Michael O'Riordan

May 23, 2022

News Conference News VIVA 2021

EMINENT: Better Patency With DES Over BMS for Fem-Pop Lesions

L.A. McKeown

October 12, 2021

News Conference News ACC 2021

Even With Stent Cards, Patients Often Hazy on PCI Details Years Later

Michael O'Riordan

May 11, 2021

News Daily News

More Risk of Death—All, Cardiac, and Noncardiac—With PCI Over Surgery: Meta-analysis

Michael O'Riordan

October 23, 2020

News Conference News TCT 2020

EXAMINATION Surprise: Few Late Event Gaps Between DES and BMS in STEMI

L.A. McKeown

October 22, 2020

News Conference News TCT 2020

Stent Polymer Face-off Calls Bioresorbable Coatings Into Question

Shelley Wood

October 17, 2020

In-Stent Restenosis Accounts for 10% of All PCIs, Contemporary National Analysis Shows

News Daily News

In-Stent Restenosis Accounts for 10% of All PCIs, National Analysis Shows

L.A. McKeown

September 24, 2020

News Daily News

‘Speaking the Same Language’: New Guidance for Trials of Patients at High Bleeding Risk

Michael O'Riordan

September 16, 2020

News Conference News ESC 2020

In Long-term, Real-world Data, CABG Bests PCI for Diabetic Patients With MVD

Yael L. Maxwell

September 01, 2020

Advertisement

Sirolimus-Coated Balloon Meets Mark in De Novo Lesions and ISR: SELUTION

Coronary DCB Works Well in Multilayer In-Stent Restenosis: AGENT IDE Subanalysis

AGENT IDE: DCB Performance for In-Stent Restenosis Lasts Out to 2 Years

DES Best for In-Stent Restenosis, but DCBs Also Viable

DCB in STEMI Match DES Through 5 Years: REVELATION

Mixed Bag With DCBs for In-Stent Restenosis, Small Coronary Arteries

Full AGENT IDE Results Affirm Benefits of DCB for In-Stent Restenosis

UK Cardiac Audit Reveals Some Good, Some ‘Appalling’ Trends in PCI

BIOSTEMI: Degradable-Polymer, Ultrathin-Strut DES Shows No Late Catch-up at 5 Years

‘Light at the End of the Tunnel’ for In-Stent Restenosis: AGENT IDE Wins Big

Long-term Data Support Paclitaxel-Coated Balloons for In-Stent Restenosis

Long-term Outcomes With PCI and CABG: More Analyses to Stir the Pot

EMINENT: Better Patency With DES Over BMS for Fem-Pop Lesions

Even With Stent Cards, Patients Often Hazy on PCI Details Years Later

More Risk of Death—All, Cardiac, and Noncardiac—With PCI Over Surgery: Meta-analysis

EXAMINATION Surprise: Few Late Event Gaps Between DES and BMS in STEMI

Stent Polymer Face-off Calls Bioresorbable Coatings Into Question

In-Stent Restenosis Accounts for 10% of All PCIs, National Analysis Shows

‘Speaking the Same Language’: New Guidance for Trials of Patients at High Bleeding Risk

In Long-term, Real-world Data, CABG Bests PCI for Diabetic Patients With MVD

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content